Before revision: The COVID-19 pandemic demands the rapid identification of drug-repurpusing candidates .
After revision: The current pandemic has highlighted the need for methodologies that can quickly and reliably prioritize clinically approved compounds for their potential effectiveness for SARS-CoV-2 infections .